Gain Therapeutics, Inc. - GANX STOCK NEWS

Gain Therapeutics (Nasdaq: GANX) announced promising pre-clinical results for its GCase-targeting therapy for neuronopathic Gaucher disease at the 19th Annual WORLD Symposium. The study demonstrated that the compound GT-02329 restores β-glucocerebrosidase (GCase) activity, reduces toxic lipid accumulation, and improves neuromuscular function. CEO Matthias Alder highlighted the consistent preclinical data and affirmed plans to submit a dossier for Phase 1 clinical trials of their lead compound GT-02287 in mid-2023. This research addresses an unmet need as current enzyme replacement therapies do not penetrate the blood-brain barrier, leaving patients vulnerable.

Gain Therapeutics, Inc. (Nasdaq: GANX) has announced plans to present new preclinical data on its lead program targeting GBA1-related diseases during several upcoming scientific meetings. CEO Matthias Alder highlighted the significant data generated in the past year, demonstrating the drug candidate GT-02287’s mechanism and potential disease-modifying effects. Presentations will take place at notable conferences including the 19th Annual WORLDSymposium from February 22-26, 2023, in Orlando, FL, and AD/PD 23 from March 28-April 1, 2023, in Gothenburg, Sweden. Gain Therapeutics aims to enter clinical development later this year.

Gain Therapeutics, Inc. (Nasdaq: GANX) announced that its CEO, Matthias Alder, will present a corporate update at the Sidoti Small-Cap Virtual Investor Conference on January 18, 2023, at 2:30 PM ET. The presentation will showcase the company’s advancements in drug discovery through its computational platform, focusing on drug-protein interactions and targeting various diseases, including Parkinson’s disease. The event can be accessed via the company’s investor relations page, with a replay available for 90 days post-event.

Gain Therapeutics (NASDAQ: GANX) recently reported its third-quarter financial results, highlighting a net loss of $4.56 million and cash reserves of $25.7 million as of September 30, 2022. The company presented promising preclinical data for GT-02287, its lead candidate for Parkinson's disease, demonstrating potential disease-modifying effects, including improved motor skills in mice. Gain anticipates beginning its Phase 1 clinical trial in mid-2023, leveraging its strong financial foundation to advance its research programs.

Gain Therapeutics (NASDAQ: GANX) announced positive preclinical data for its investigational small molecule therapeutic, GT-02287, targeting Parkinson’s Disease. Presented at the Shaare Zedek Medical Center symposium, the study demonstrated significant increases in GCase levels and reductions in α-synuclein aggregates using patient-derived neurons. This suggests GT-02287 may correct GBA1 mutations, which affect 14% of Parkinson's patients. The findings support GT-02287's potential as a disease-modifying treatment, reinforcing Gain's approach using its proprietary computational drug discovery platform.

Gain Therapeutics, Inc. (NASDAQ: GANX) has appointed Matthias Alder as its new Chief Executive Officer, effective immediately, following the departure of Eric Richman, who will remain on the board and serve as a senior advisor. Alder, the former Chief Operating Officer, brings over 25 years of experience in the pharmaceutical sector. His leadership is anticipated to drive the company's growth strategy and advance key programs targeting Parkinson's and Gaucher diseases. The board size has increased to eight members with Alder's appointment.

Gain Therapeutics (Nasdaq: GANX) presented preclinical data on GT-02287 at the International Congress of Parkinson’s Disease and Movement Disorders 2022 Annual Meeting. Results demonstrated a significant dose-dependent improvement in lysosomal health and fine motor skills in Parkinson’s disease models. GT-02287 shows promise in neutralizing CBE-mediated neurodegeneration and enhancing neuronal survival. This research indicates the potential for GT-02287 as a first-in-class disease-modifying therapy, aiming to restore enzyme function in Parkinson’s patients.

Gain Therapeutics, Inc. (Nasdaq: GANX) is set to present preclinical data at two significant medical meetings in September 2022. The first presentation will occur at the MDS 2022 International Congress in Madrid on September 17, featuring a poster on GT-02287, a promising allosteric regulator for Parkinson's disease. The second presentation will be at the GBA-PD Symposium in Jerusalem on September 22, discussing innovative strategies for GBA-PD. Gain's approach employs its unique computational discovery platform, SEE-Tx®, to drive advancements in drug development.

Gain Therapeutics (Nasdaq: GANX) announced that COO Matthias Alder will present at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022, in New York. The presentation is scheduled for September 12 at 7:00 AM ET and will be available via a webcast. Gain Therapeutics focuses on transforming drug discovery with its proprietary SEE-Tx® platform, targeting allosteric binding sites to develop treatments for various diseases, including neurodegenerative and metabolic disorders.